Catalyst Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Catalyst Pharmaceuticals has a total shareholder equity of $608.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $706.4M and $97.7M respectively. Catalyst Pharmaceuticals's EBIT is $85.9M making its interest coverage ratio -10.6. It has cash and short-term investments of $375.7M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -10.6x |
Cash | US$375.69m |
Equity | US$608.66m |
Total liabilities | US$97.71m |
Total assets | US$706.36m |
Recent financial health updates
No updates
Recent updates
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jul 24Catalyst Pharmaceuticals: New Products In Proving Phase
Jul 06Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition
Sep 12Catalyst Pharma ends momentum as Roth downgrades
Aug 24Financial Position Analysis
Short Term Liabilities: CPRX's short term assets ($474.4M) exceed its short term liabilities ($92.3M).
Long Term Liabilities: CPRX's short term assets ($474.4M) exceed its long term liabilities ($5.4M).
Debt to Equity History and Analysis
Debt Level: CPRX is debt free.
Reducing Debt: CPRX has not had any debt for past 5 years.
Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.